Zephyr AI Raises $18.5M to Advance Precision Medicine, Drug Discovery
The startup healthcare company will leverage big data and its machine learning model to transform precision medicine and drug discovery.
Source: Getty Images
By - Zephyr AI, a health IT startup, landed $18.5 million in seed round funding to advance precision medicine and drug discovery through machine learning and extensive data sets.
The $18.5 million round was led by Lerner Group Investments LLC and M-Cor Holdings, with participants from Allen Y Chao, AME Cloud Ventures, BoxGroup, MedStar Health, Roger W. Ferguson, Steve Oristaglio, Verily, and other strategic investors.
“The team at Zephyr AI impresses us with its unique and innovative approach to harnessing the predictive power of Artificial Intelligence and big data in healthcare settings,” Michael L. Cohen, vice president of investments at Lerner, said in a public statement.
“Zephyr AI has the proven ability to generate and validate a remarkable breadth of extraordinary insights,” Cohen added. “We are very pleased to co-lead this funding round and help realize the profound potential for this technology in disease mitigation and treatment.”
In 2021, Red Cell Partners founded Zephyr. The company has been putting in extensive effort to build an unrivaled multidisciplinary team of data scientists, computer and software engineers, and computational and molecular biologists to advance a proprietary suite of cutting-edge technologies.
“This successful funding round reflects investors’ collective confidence in Zephyr AI’s world-class data science and future as a much larger business,” Josh Lobel, CEO, and CIO of M-Cor Holdings, said in the press release. “Zephyr AI’s vision and expertise promise to transform patient care in critical areas such as diabetes and cancer. As an organization deeply committed to being at the forefront of successful initiatives in medical research, we are delighted to be participating.
The company uses big data, machine learning, and analysis of structured biological networks and longitudinal outcomes to draw new insights targeting patient care, patient outcomes, and drug development cost, the press release stated.
The startup will be prioritizing industry partnerships to increase its data access and machine-learning pipelines. By gathering additional datasets, Zephyr AI can generate insight for better outcomes in patient care and drug discovery.
Organizations are constantly looking for ways to enhance treatment and patient experience.
In 2021, AccessDX Holdings acquired health IT vendor Allscripts’ precision medicine platform to boost its clinical decision support offerings.
The 2bPrecise platform delivers point-of-care insights within the clinical workflow of any EHR system that help providers identify patients at risk for heritable conditions.
The precision medicine platform aims to provide quicker and more precise diagnoses so providers can begin optimal treatment more promptly, advancing care delivery.
